Y-90 Microsphere (TARE) Therapy Receives FDA Approval for Inoperable Liver Cancer

This dual indication demonstrates that Y-90 therapy is effective and safe across a broad patient population .

Targeted Radiotherapy with Personalized Dosimetry

Radioembolization , also known as selective internal radiation therapy (SIRT), is based on microscopic spheres containing Yttrium-90 (Y-90) delivering high-dose beta radiation directly to tumors in the liver.

Interventional radiologists guide these spheres to the tumor via a catheter inserted through the femoral artery, reaching the hepatic artery that supplies the liver. Because of the tumor’s high vascular density , microspheres accumulate primarily in tumor tissue while causing minimal harm to healthy tissue. This method uses personalized dose calculations, adjusted according to tumor volume, liver function and vascular anatomy. This optimizes both efficacy and the safety profile .

The DOORwaY-90 Study: Scientific Evidence Establishing Efficacy and Safety

FDA approval is based on the prospective, multicenter study conducted at 18 US centers, DOORwaY-90 . The study enrolled patients who had not previously received systemic treatment: 100 patients with HCC were assessed for the safety and efficacy of Y-90 microspheres.

Eligibility Criteria:

• Unresectable tumors
• Ineligible for ablation methods such as RFA or MWA
• BCLC stage A, B1, B2 or selected C (limited portal vein thrombosis or limited extrahepatic spread)
• Child-Pugh A5/A6 and ECOG 0–1
• Maximum single-tumor diameter < 8 cm; total tumor diameter < 12 cm

Study co-investigator Dr. Armeen Mahvash stated:

“This study advances the field of radioembolization, delivering reproducible dosimetry, a strong safety profile and promising clinical outcomes.”

Who Benefits Most from Y-90 Microspheres?

Y-90 microsphere therapy is particularly suitable for the following patient profile:

• No macrovascular invasion
• Child-Pugh A cirrhosis and good liver reserve
• ECOG 0–1 performance status
• Limited or no extrahepatic disease

It is important to emphasize that this treatment is a local approach aimed primarily at controlling tumor burden in the liver. In patients with systemic spread , its effect is limited.

Other Approved Treatment Options in HCC and Survival Data

Although Y-90 microspheres are an important advance, other FDA-approved systemic and local treatments are also available for unresectable HCC:

Systemic Treatments:

• Nivolumab + Ipilimumab: Median OS ≈ 23.7 months
• Atezolizumab + Bevacizumab: OS ≈ 19.2 months
• Durvalumab + Tremelimumab (STRIDE): OS ≈ 16.4 months
• Lenvatinib: OS ≈ 13.6 months
• Sorafenib: OS ≈ 10.7–13.4 months
• Cabozantinib, Regorafenib, Ramucirumab: OS ≈ 9–10 months

Local Treatments:

• TACE (Transarterial chemoembolization): OS ≈ 20–30 months, PFS ≈ 10.3 months (with immunotherapy)
• RFA / MWA: 5-year OS ≈ 50–70%, local recurrence-free survival ≈ 1–3 years

Conclusion: A New Era in Personalized Liver Cancer Treatment

The FDA’s approval of Y-90 resin microspheres once again highlights the importance of personalized and targeted liver cancer treatments.

With high local control rates, prolonged response durations and a low toxicity profile, this treatment stands out as a valuable option for patients with unresectable HCC.

Within multidisciplinary treatment approaches, this innovative method will further strengthen its position, offering new hope to both patients and physicians in the fight against liver cancer.